| Risk Factors
Tardive dyskinesia (TD) is a neurologic syndrome. It results from using neuroleptic drugs—also called antipsychotic drugs. This class of drugs is used to treat psychiatric conditions, like
schizophrenia. TD consists of a group of symptoms including:
- Abnormal twisting movements
- Abnormal postures due to sustained muscle contractions
It is unclear exactly why TD develops. Long-term use of neuroleptic drugs can cause changes in the chemistry in the brain that lead to the symptoms. Nerve cells may also become overly sensitive to certain substances, such as neurotransmitters in the brain. Not everyone who takes these drugs develops TD.
Factors that may increase your risk of TD include:
Use of neuroleptic drugs, especially if the drugs:
- Are taken in high doses and longer than six months
- Are first generation drugs
and prochlorperazine—These medicines are used to treat gastrointestinal problems, like nausea, vomiting, delayed bowel emptying, and
gastroesophageal reflux disease
(GERD), especially if taken more than three months.
- Age: 54 or older
- Sex: female
- Possible genetic factor
Having a disease that may require using neuroleptic drugs, such as:
- Mood disorders
or other psychiatric disorders
Behavior problems that occur with psychiatric or neurologic disorders, such as agitation in
Digestive disorders such as:
caused by neuroleptic drugs
TD causes repetitive movements. Movements usually occur in the face, mouth, limbs, or trunk. The movements are involuntary and serve no purpose. They may occur occasionally or all of the time. They may or may not be noticeable. Symptoms may begin while on the drug or within weeks of stopping it. They can worsen with:
- Moving other parts of the body
- Taking certain drugs
Symptoms my decrease with:
- Purposely moving the affected body part
Symptoms may include:
- Sticking out the tongue
- Twisting the tongue
- Smacking lips
- Puckering lips
- Blinking eyes
- Facial tics
- Foot tapping
- Moving fingers as if playing the piano
- Rapidly moving arms, legs, or body
- Writhing movements
- Pelvic thrusts
- Noisy breathing
The doctor will ask about your symptoms and medical history. A physical exam will be done. Other disorders can cause symptoms similar to those of TD. The doctor will rule out other disorders before making a diagnosis. There is no specific test for TD.
Tests may include:
- Your bodily fluids may be tested. This can be done with blood tests.
Pictures may be taken of structures inside your head. This can be done with:
CT Scan of the Head
Copyright © Nucleus Medical Media, Inc.
To treat TD, your doctor may:
- Stop the neuroleptic medicine
- Lower the dose
- Switch you to a different medicine, such as an atypical antipsychotic
to reduce the risk of worsening symptoms—These vitamins are still being studied.
Symptoms may decrease over time even if you continue to take the neuroleptic drug. Younger people tend to do better.
Some medicines may help decrease symptoms, such as:
Sedatives, such as:
Antiseizure drugs, such as:
- Valproic acid
- Antipsychotic drugs that may help with movement disorders, such as sulpiride, oxypertine, tiapride and other medicines, such as L-dopa, which is a type of amino acid.
Deep Brain Stimulation (DBS) is being evaluated for the treatment of TD.
If you need neuroleptic drugs to control a psychiatric disorder, consider these guidelines to help prevent TD:
Talk with your doctor about:
- Risks and benefits of the medicine
- Whether the dose is right for you and how well the drug is working
- Other medicines you can try that have less risk of TD
- Whether you can take a drug holiday, to take a break from using the medicine
- Even a small symptom of TD that you have—Early treatment works best.
- Do not stop taking your medicine without first talking to your doctor. If you stop the drug right away, it may trigger TD.
- See your doctor every three months.
Bai YM, Yu SC, Lin CC.
Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
J Clin Psychiatry. 2003;64:1342-1348.
Bradley WG, Daroff RB, Fenichel G, Jankovic J.
Neurology in Clinical Practice.
4th ed. Butterworth Heinemann; 2003. Accessed November 4, 2007.
Cecil RL, Goldman L, Bennett JC.
Cecil Textbook of Medicine. 21st ed. Philadelphia, PA: WB Saunders Co; 2000.
Conn HF, Rakel RE.
Conn's Current Therapy 2001. 53rd ed. Philadelphia, PA: WB Saunders Co; 2001.
Griffith's 5-Minute Clinical Consult. Baltimore, MD: Lippincott Williams & Wilkins; 2001.
Damier P. Drug-induced dyskinesias.
Curr Opin Neurol. 2009;22(4):394-399.
Goroll A, Mulley A.
Primary Care Medicine. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000.
Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H.
Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods.
Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:985-996.
McGrath JJ, Soares KV. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
Database Syst Rev. 2006;CD000459.
Meco G, Fabrizio E, Epifanio A, et al. Levetiracetam in tardive dyskinesia.
Clin Neuropharmacol. 2006;29:265-268.
Noble J, Greene HL.
Textbook of Primary Care Medicine. 3rd ed. St. Louis, MO: Mosby Inc; 2001.
Pham DQ, Plakogiannis R. Vitamin E supplementation in Alzheimer’s disease, Parkinson’s disease, tardive dyskinesia, and cataract: part 2.
Ann Pharmacother. 2005;39(12):2065-72.
Sachdev PS. The current status of tardive dyskinesia.
Australian and New Zealand Journal of Psychiatry. 2000;34:355-369.
Soares KV, McGrath JJ. The treatment of tardive dyskinesia: a systematic review and meta-analysis.
Tardive dyskinesia. EBSCO DynaMed website. Available at:
http://www.ebscohost.com/dynamed/. Updated November 23, 2011. Accessed February 25, 2013.
Tardive dyskinesia. National Alliance on Mental Illness website. Available at:
http://www.nami.org/Content/ContentGroups/Helpline1/Tardive_Dyskinesia.htm. Updated September 2003. Accessed February 25, 2013.
Tasman A, Kay J, Lieberman J.
Psychiatry. Philadelphia, PA: WB Saunders Co; 1997.
Thema B, Srivastava V, Tiwari AK. Genetic underpinnings of tardive dyskinesias: passing the baton to pharmacogenetics.
Last reviewed March 2013 by Rimas Lukas, MD
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.